1. AB0268 Lack of correlation between golimumab exposure and selected safety events following intravenous or subcutaneous administration in an integrated analysis of phase 3 data in rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. (23rd January 2014) Authors: Leu, J. H.; Beutler, A.; Mendelsohn, A.; Liao, S.; Davis, H.; Zhou, H.; Xu, Z. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A868 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0269 Importance of steady-state trough concentrations after intravenous golimumab with concomitant methotrexate in patients with active rheumatoid arthritis. (23rd January 2014) Authors: Leu, J. H.; Xu, Z.; Hu, C.; Mendelsohn, A.; Ford, J.; Davis, H. M.; Zhou, H. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A868 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0284 Long term safety of iv golimumab and comparisons with sc golimumab in rheumatologic conditions: results from the 120-day safety report of go-further trial. (23rd January 2014) Authors: Westhovens, R.; Bingham, C. O.; Weinblatt, M.; Fleischmann, R.; Keystone, E.; Hsia, E. C.; Hsu, B.; Kim, L.; Mudivarthy, S.; Mack, M.; Goldstein, N.; Braun, J.; Kavanaugh, A.; Mendelsohn, A.; Kay, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A873 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0398 Efficacy of Adalimumab and Tofacitinib in Rheumatoid Arthritis: Post-Hoc Analyses from A Phase 3 Study. (15th July 2016) Authors: van Vollenhoven, R.; Cohen, S.; Mendelsohn, A.; Bananis, E.; Fan, H.; Takiya, L.; Fleischmann, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0747 Early and Sustained Modified PSARC Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from PSUMMIT 1 and PSUMMIT 2. (10th June 2014) Authors: McInnes, I.; Ritchlin, C.; Rahman, P.; Puig, L.; Gottlieb, A.B.; Song, M.; Randazzo, B.; Li, S.; Wang, Y.; Mendelsohn, A.; Kavanaugh, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 1051 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis. (12th June 2018) Authors: Blauvelt, A.; Sofen, H.; Papp, K.; Gooderham, M.; Zhao, Y.; Lowry, S.; Mendelsohn, A.; Parno, J.; Li, Q.; Rosa, C.L.; Reich, K. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FRI0132 Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results Through 2 Years. (9th June 2015) Authors: Westhovens, R.; Keystone, E.; Bingham, C.O.; Hsia, E.C.; Kim, L.; Zhou, Y.; Mendelsohn, A.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 469 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0266 Health-Related Quality of Life of Patients with Rheumatoid Arthritis Achieving DAS28 Remission, Improvement in Physical Function and NO Radiographic Progression after Treatment with Intravenous Golimumab. (10th June 2014) Authors: Westhovens, R.; Weinblatt, M.E.; Han, C.; Kim, L.; Mack, M.; Lu, J.; Baker, D.; Mendelsohn, A.; Bingham, C.O. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP0001 Maintenance of Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1 Yr Results of the Psummit 2 Trial. (23rd January 2014) Authors: Ritchlin, C.; McInnes, I.; Kavanaugh, A.; Puig, L.; Rahman, P.; Li, S.; Shen, Y.; Doyle, M.; Mendelsohn, A.; Gottlieb, A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0229 Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy. (9th June 2015) Authors: Winthrop, K.; Lindsey, S.; Fan, H.; Wang, L.; Gelone, D.; Mendelsohn, A.; Bananis, E.; Curtis, J. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 741 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗